Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy-Reference-Cited by-同舟云学术

Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy

Published:2020-07 Issue:1 Volume:76 Page:66-72
ISSN:0914-5087
Container-title:Journal of Cardiology
language:en
Short-container-title:Journal of Cardiology

Author:

Matsushita Kensuke^ORCID,Hibi Kiyoshi,Komura Naohiro,Kimura Yuichiro,Matsuzawa Yasushi,Konishi Masaaki,Maejima Nobuhiko,Iwahashi Noriaki,Kosuge Masami,Ebina Toshiaki,Tamura Kouichi,Kimura Kazuo

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Cdna sequence of human apolipoprotein(a) is homologous to plasminogen;McLean;Nature,1987

2. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention;Konishi;Am J Cardiol,2015

3. Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: Re-revascularization rate is high in patients with high-lp(a);Morita;Circ J,2006

4. Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction;Mitsuda;Heart Vessels,2016

5. Effects of evolocumab (amg 145), a monoclonal antibody to pcsk9, in hypercholesterolemic, statin-treated japanese patients at high cardiovascular risk--primary results from the phase 2 yukawa study;Hirayama;Circ J,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current trends in solving the problem of residual cardiovascular risk;Meditsinskiy sovet = Medical Council;2024-05-19

2. Lipid-lowering Therapy and Coronary Plaque Regression;Journal of Atherosclerosis and Thrombosis;2024

3. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients With Acute Myocardial Infarction;Circulation Journal;2023-09-25

4. Lipoprotein(a) variations between Chronic Coronary Syndrome and Acute Myocardial Infarction and their relation to the severity of coronary artery stenosis;2022-11-16

5. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study;Clinical Therapeutics;2022-09